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Abstract
Background: The pathogenesis of diabetic neuropathic pain is complicated and its underlying mechanisms remain
unclear. Calmodulin-dependent protein kinases (CaMKs) IV (CaMKIV), one of CaMKs, regulates several transcription
factors in pain mechanisms. High-mobility group box 1 (HMGB1) is a key mediator in diabetic neuropathic pain.
This study aims to find the roles and mechanisms of CaMIV in diabetic neuropathic pain.
Methods: Diabetic animal models were constructed by injecting with streptozotocin (STZ) intraperitoneally. They
were randomly divided into seven groups (n = 6 per group): Naive, Normal Saline, STZ, STZ + Sham, STZ + DMSO
and STZ + KN93 (an inhibitor of CaMKIV) (50 μg), STZ + KN93 (100 μg), which received KN93 (50 or 100 μg)
intrathecally after the administration of STZ. Phospho-CaMKIV (pCaMKIV) and HMGB1 expression in rat dorsal root
ganglion (DRG) and RAW264.7 cell line were measured by western blot. Distribution of pCaMKIV immune reactivity
in different subpopulations of DRG neurons was measured by double-immunofluorescence staining.
Results: The pCaMKIV and HMGB1 in DRG significantly increased after STZ administration, and pCaMKIV can
regulate the expression of HMGB1 based on both cellular and animal models. Pretreatment with CaMKIV inhibitor
attenuated STZ-induced mechanical allodynia and thermal hyperalgesia, as well as reduced HMGB1 expression in
the DRG.
Conclusions: This study demonstrates that CaMKIV can relieve STZ-induced diabetic neuropathic pain. The
mechanism of this function depended on the process: pCaMKIV localized in the nuclei of DRG neurons and
regulated HMGB1 which was an important mediator of neuropathic pain. These findings reported CaMKIV
may be a potential target or important node in relieving diabetic neuropathic pain.
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Background
Diabetic neuropathic pain is one of the most common
complications of both type 1 and type 2 diabetes. How-
ever, information regarding diabetic neuropathy is insuf-
ficient to propose an efficient therapy for such chronic
pain. To further understand the mechanisms underlying
the development of diabetic neuropathy, type 1 and type
2 diabetes animal models have been used to study this
phenomenon [1, 2]. Streptozotocin (STZ)-induced type
1 diabetes is a typical model for diabetic neuropathy,
because systemically administered STZ exerts a cyto-
toxic effect on pancreatic β cells [3].
Calmodulin-dependent protein kinases (CaMKs),
including CaMKI, CaMKII and CaMKIV, are important
mediators of intracellular Ca2+ signaling, which per-
form important roles in cell physiology. These serine-
threonine (Ser/Thr) protein kinases are activated upon
Ca2+/CaM binding [4]. CaMKI and CaMKII are expressed
in all mammalian cells [5]. CaMKIV is found predomin-
ately in cells of the nervous and immune systems [6].
* Correspondence: garybeijing@163.com
1Department of Anesthesiology, Peking Union Medical College Hospital,
CAMS&PUMC, No.1, Wangfujing, DongCheng District, Beijing 100730, China
Full list of author information is available at the end of the article
© 2016 Zhao et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhao et al. BMC Anesthesiology  (2016) 16:27 
DOI 10.1186/s12871-016-0191-4
CaMKIV is activated and translocated into the nucleus
upon its phosphorylation by an upstream CaMKs kinase
(CaMKK) in the cytoplasm [7]. The nuclear, autonomously
active form of CaMKIV phosphorylates numerous pro-
teins involved in transcription regulation [8]. However,
the effects of CaMKIV on neuropathic pain remain
unclear.
High-mobility group box 1 (HMGB1) is a DNA-binding
protein located in the nuclei of most mammalian cells.
HMGB1 performs structural and transcriptional activities
by binding to chromatin. Moreover, HMGB1 is either
actively secreted or can be passively released by injured or
necrotic cells [9]. Emerging evidence has shown that
HMGB1 is a proinflammatory mediator of chronic pain
development, including neuropathic pain [9]. In db/db
mice, a model of type 2 diabetes, the development of mech-
anical allodynia is associated with the upregulation of
HMGB1 protein in the spinal cord, and intrathecal injec-
tion of the neutralizing antibody against HMGB1 inhibited
mechanical allodynia [10]. However, whether CaMKIV is
involved in STZ induced neuropathic pain through modu-
lation of spinal HMGB1 in rats remains unclear.
The present study investigated the effects of CaMKIV
on diabetic neuropathic pain, as well as the relationship
of CaMKIV with HMGB1 expression in dorsal root gan-
glion (DRG). STZ-induced diabetic models were imployed
to investigate the variation of pCaMKIV and HMGB1 in
DRG via Western blot (WB) and immunehistochemical
(IHC) assays. KN93, an inhibitor of CaMKIV [11], and
CaMKIV-siRNA were also used to study the relationship
between pCaMKIV and HMGB1. The results indicated
that CaMKIV is involved in STZ-induced diabetic neuro-
pathic pain via regulation of HMGB1.
Methods
Animals
Male Sprague–Dawley rats (180 g to 200 g) were
purchased from the Experimental Animal Center of the
Chinese Academy of Medical Sciences. The animals
were allowed to adapt to the laboratory for minimus of
2 h prior to testing, and used only once. All animal pro-
cedures and experimental protocols in this study were
approved by the “Institutional Animal Care and Use
Committee (IACUC)” of Chinese Academy of Medical
Sciences (“Tab of Animal Experimental Ethical Inspec-
tion” number: Acuc-A02–2015–005; IACUC Chairman:
Minli Li). All protocols were also consistent with the
NIH Guide for Care and Use of Laboratory Animals
(NIH Publication No. 80–23).
Intrathecal catheter implant surgery
Each rat was anesthetized with 50 mg/kg sodium pento-
barbital intraperitoneally (i.p.) and an intrathecal catheter
was implanted as described by Yaksh and Rudyb [12].
Briefly, a polyethylene tubing (PE-10) filled with sterile
normal saline was inserted through a small incision on the
atlantooccipital membrane and extended caudally to the
lumbar enlargement of the spinal cord. Studies involving
rats with chronic intrathecal catheters were conducted
after implantation. Rats were monitored daily for signs of
neural dysfunction and were removed from the study if
neurological dysfunction was noted. Overall, no animals
were excluded in the diabetic model experiments.
Induction and assessment of diabetes in rats
Experimental diabetes was induced by a single i.p. injec-
tion of STZ (Sigma-Aldrich Co., St. Louis, MO, USA).
The STZ solution was prepared freshly by dissolving
normal saline and was injected intraperitoneally at a dose
of 65 mg/kg on the seventh day after surgery as previously
described [13]. Diabetes induction was assessed by weekly
measurement of the tail vein blood glucose level by using
a blood glucose meter (HEA-214, OMRON, USA). Body
weight was also monitored. Only rats with blood glucose
concentration exceeding 240 mg/dL were considered
diabetic and used for the study.
The effect of KN93 on diabetic models
The rats were randomly divided into seven groups (n = 6
per group): Group Naive; Group Normal Saline (NS),
which received only the NS; Group STZ, which received
STZ; Group STZ + Sham, which sham operation after
administration of STZ; Group STZ +DMSO, which
received DMSO intrathecally after the administration of
STZ; Group STZ + KN93 (50 μg), which received KN93
(50 μg) intrathecally after the administration of STZ;
Group STZ + KN93 (100 μg), which received KN93
(100 μg) intrathecally after the administration of STZ.
KN93 obtained from Calbiochem was dissolved in
sterile DMSO 20 μl and injected intrathecally on 15,
17, 19 days after the STZ administration respectively.
The dose of KN93 was chosen based on previous
publications [14].
Behavioral tests
Paw mechanical withdrawal threshold (MWT) was
used to measure mechanical allodynia and was
assessed by testing the left hind paw withdrawal re-
sponse to Electronic Von Frey filaments (Stoelting
Co., USA). Brisk withdrawal or paw flinching was
considered a positive response. Each rat was tested
five times per stimulus strength.
Paw thermal withdrawal latency (TWL) was used to
measure thermal hyperalgesia and performed by using a
heat pain stimulator (PL-200, Taimen Biotech Company,
Chengdu). The measurement was repeated five times for
each rat (interval ≥ 5 min), and the mean was calculated
as PWL for this measurement.
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Western blot analysis
Total protein was extracted from the L4 and L5 DRGs
using methods described earlier [15]. The primary anti-
bodies against pCaMKIV, CaMKIV, HMGB1 (1:500; Santa
Cruz, USA) were used in Western blot (WB). To verify
equal loading of protein, the blots were reprobed with pri-
mary monoclonal antibody against β-actin (ProteinTech
Company, USA).
Immunohistochemistry
Immunofluorescent labeling of the following markers
was performed on different group rat lumbar DRG cryo-
sections using the methods as previously described [16].
The primary antibodies in the immunohistochemistry:
rabbit polyclonal and mouse monoclonal antibodies
against pCaMKIV, HMGB1, isolectin B4 (IB4), protein
gene product 9.5 (PGP9.5), calcitonin gene-related peptide
(CGRP), 1:200, Santa Cruz. The secondary antibodies
used: Alexa Fluor 555-conjugated donkey-anti-mouse,
1:500; Alexa Fluor 488-conjugated donkey-anti-rabbit,
1:500, Invitrogen.
The cells were visualized using a laser confocal micro-
scopic imaging system (Nikon A1; Nikon Co.Ltd., Tokyo,
Japan) with a water immersion 10 objective lens (Plan
Apo 60x1.20 PFS WI) and a 1 st dichroic mirror (405/
488/561/640). The green signal was excited by 488 nm
light from an Ar laser and red signal was excited by
561 nm light from a DPSS laser. The images were 400
times magnification and the scale bar in Fig. 4 was 20 μm.
Transfection of siRNA
RAW 264.7 cells (2*104) were plated in 0.5 ml of
growth medium (without antibiotics) in each well of a
24-well plate. The sequence of negative control siRNA
(N.C. siRNA) and CaMKIV siRNA obtained from
Zhang X et al. [11]. The protocol is also comes from
Zhang X [11].
Statistical analysis
Data were presented as means ± standard deviation. A
behavioral test was evaluated by two-way repeated
measures analysis of variance (ANOVA). The expres-
sion of pCaMKIV and HMGB1 were analyzed by one-
way or two-way ANOVA with Student Newman Keuls
post hoc analysis. P-values of <0.05 were considered
statistically significant.
Result
Validation of diabetic models
At 14 days after STZ injection, the blood glucose
level of the STZ group was significantly higher than
those of the Naive and NS groups (Fig. 1a) (P < 0.05).
STZ-injected rats exhibited a significant reduction of
weight gain relative to those of Naive and NS groups
after 1 month (Fig. 1b) (P < 0.05). To confirm damage to
the nervous system, MWT was measured, and a significant
decrease in MWT was found in diabetic rats after 14 days
of STZ injection as compared with the Naive and NS
groups (Fig. 1c) (P < 0.05). Marked TWL was also observed
in diabetic animals, as evidenced by a reduction in pain
thresholds, compared with the Naive and NS groups after
14 days (Fig. 1d) (P < 0.05). These results suggest that the
STZ-induced diabetic model can be used in this research.
pCaMKIV expression was significantly increased in
diabetic models
The pCaMKIV levels in DRG were investigated by Western
blot and showed a significant increase in diabetic models,
whereas the CaMKIV expression level did not exhibit
considerable change. Gray scanning displayed a marked
change in pCaMKIV levels after STZ treatment (Fig. 2a).
The level of HMGB1, which is an important regulator of
neuropathic pain, increased after STZ treatment, and this
finding occurred simultaneously with pCaMKIV (Fig. 2b).
pCaMKIV regulates HMGB1 expression
Whether pCaMKIV can regulate the expression of
HMGB1 is an important topic in this research. For
further investigation, KN93 was used for incubation
with RAW264.7 cell line at different concentrations
(Fig. 3a). In particular, pCaMKIV significantly decreased
with the increase in KN93 concentration. HMGB1 expres-
sion also decreased with pCaMKIV. The specific CaMKIV
siRNA was also used in this experiment. Fig. 3b shows the
siRNA-CaMKIV can decrease the expression of CaMKIV,
and pCaMKIV was similarly reduced. These results sug-
gest that the siRNA of CaMKIV functioned well. The
expression of HMGB1 was detected by Western blot and
decreased significantly compared with the control (Fig. 3b).
These results imply that pCaMKIV can regulate the
expression of HMGB1.
pCaMKIV is localized in the nuclei of DRG neurons
To further investigate the mechanisms of pCaMKIV and
the expression of pCaMKIV in DRG neurons, immuno-
histochemical (IHC) analysis was perfomed to confirm
pCaMKIV localization. Neuronal markers PGP9.5, IB4,
and CGRP were investigated by IHC in this research.
Fig. 4a to C show the colocalization of PGP9.5 and
pCaMKIV, whereas Fig. 4d to f and g to I display the
colocalization of IB4 and pCaMKIV and that of CGRP
and pCaMKIV, respectively. These results suggest that
pCaMKIV may be an important regulator in neurons.
Effect of intrathecal administration of KN93 on diabetic
models
KN93, a pCaMKIV inhibitor [11], was used to investigate
the function of pCaMKIV in diabetic models. KN93 was
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injected intrathecally at 15, 17 and 19 days after STZ
administration; however, the blood glucose and weight
gain did not change significantly following STZ ad-
ministration. Pretreatment with KN93 inhibited STZ-
induced mechanical allodynia and thermal hyperalgesia
in a time-dependent manner after STZ administration
(P < 0.05) (Fig. 5).
To further investigate the relationship among pCaM-
KIV, CaMKIV and HMGB1, Western blot was used to
determine the change in these proteins (Fig. 6). The
expression of pCaMKIV and HMGB1 was shown to
increase in DRG after STZ injection. After the intra-
thecal administration of KN93 (100 μg), the expression
of pCaMKIV in DRG decreased significantly following
STZ injection. The HMGB1 expression levels also
decreased after KN93 treatment.
Discussion
In the current study, the i.p. injection of STZ induced
diabetic neuropathic pain model in rats, as well as
increased CaMKIV phosphorylation and HMGB1 ex-
pression levels in DRG neurons. In addition, pCaMKIV
can regulate the expression of HMGB1. When KN93, a
CaMKIV inhibitor, was used in neuropathic pain models,
STZ-induced mechanical allodynia and thermal hyper-
algesia were inhibited. CaMKIV phosphorylation and
HMGB1 expression levels also significantly decreased.
Previous reports have indicated that CaMKIV may be a
Fig. 1 Changes in blood glucose level, body weight, MWT, and TWL in STZ-induced diabetic rats. a. Diabetes induction was assessed by measurement
of blood glucose level by using a blood glucose meter. b. Changes in body weight in control and diabetic rats. c. STZ-induced mechanical allodynia.
d. STZ-induced thermal hyperalgesia. The data are presented as means ± SD. Naive, group naive; NS, group NS, which received only the NS; Group STZ,
which received STZ; *P < 0.05 compared with the Naive and NS groups, n = 6 per group
Fig. 2 Changes in pCaMKIV and HMGB1 expression in DRG of STZ-induced diabetic rats, as detected by Western blot. a. Upregulation of pCaMKIV,
but not CaMKIV after STZ injection. b. Upregulation of HMGB1 after STZ injection. Data are presented as means ± SD. *P < 0.05 compared with the
Naive and NS groups, n = 6 per group
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regulator of HMGB1 [11, 17], but the specific mechanisms
remain unclear. These results will provide evidence re-
garding the relationship between CaMKIV and HMGB1.
The present study is the first to demonstrate that
pCaMKIV is involved in STZ-induced neuropathic pain
in rats. CaMKIV exists in the nuclei of cells and is asso-
ciated with several transcription factors, such as cyclic-
AMP response element-binding protein, AP-1, myocyte
enhancer factor 2A, and retinoid orphan receptor family
members, which perform pivotal functions in immune
Fig. 3 pCaMKIV can regulate HMGB1 expression. a. Effects of KN93 on the expression of pCaMKIV, CaMKIV and HMGB1 in the RAW264.7 cell line.
b. Effects of CaMKIV-siRNA on the expression of pCaMKIV, CaMKIV and HMGB1 in the RAW264.7 cell line. The results were selected from triplicates
of independent experiments
Fig. 4 Distribution of pCaMKIV immunereactivity in different subpopulations of DRG neurons at 30 days after STZ treatment. a to i.
Double-immunofluorescence staining shows the distribution of pCaMKIV immunereactivity in different subsets (PGP9.5, IB4, CGRP) of DRG
neurons in rats. The images were 400 times magnification and the scale bar was 20 μm
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response and inflammation [18]. Jackson and Damaj
found CaMKIV involvement in both spinal and suprasp-
inal mechanisms of nicotine-induced antinociception;
their results suggest that supraspinal nicotine-induced
pain mechanisms involve CaMKIV to a larger extent
than CaMKII [19]. The current research demonstrated
that pCaMKIV in DRG neurons increased in the STZ-
induced diabetic neuropathic pain model. This finding
suggests that the phosphorylation of CaMKIV is an
important regulator in neurons.
The present results also indicated that HMGB1 expres-
sion increased in the DRG of STZ-induced type 1 diabetes,
rat model, and this finding is consistent with previous re-
ports [20, 21]. However, the mechanism of HMGB1 release
in STZ-induced diabetic neuropathic pain model remains
unknown. Shibasaki et al. showed that HMGB1 expression
Fig. 5 Effects of intrathecal injection of KN93 on blood glucose levels, body weights, mechanical allodynia and thermal hyperalgesia of STZ-induced
diabetic rats. a. Changes in blood glucose levels after KN93 treatment. b. Effect of body weight after KN93 treatment. c. Effect of KN93 (100 μg) on
STZ-induced mechanical allodynia. d. Effect of KN93 (100 μg) on STZ-induced thermal hyperalgesia. Data are presented as means ± SD. #P < 0.05 in
comparison to the 0 day time point, n = 6 per group.*P < 0.05 in comparison with the DMSO group at the same time points, n = 6 per group. (i.t.cat:
intrathecal catheterization; i.t.inj: intrathecal injection; STZ: streptozotocin intraperitoneal injection)
Fig. 6 Effects of intrathecal injection of KN93 on the expression levels of pCaMKIV and HMGB1 in DRGs from STZ-induced diabetic rats. a. Expression
of pCaMKIV after KN93 treatment. b. Expression of HMGB1 after KN93 treatment. The results were selected from triplicates of independent experiments
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increased in the peripheral nerves in response to nerve
injury and suggested that this protein contributes to the
development of pain hypersensitivity, as revealed by anti-
HMGB1 antibody treatment in the neuropathic pain model
[20]. In addition, IHC studies demonstrated that HMGB1
levels are upregulated in satellite cells and neurons of
the DRG. These results provided a basis to identify the
mechanism of HMGB1 in type 1 diabetes.
HMGB1 release is an active process, by which HMGB1
is shuttled from the nucleus to the cytoplasm and then
out of DRG neurons. The current results demonstrate that
intrathecal administration of KN93, attenuates STZ-
induced diabetic neuropathic pain, CaMKIV phospho-
rylation level, and HMGB1 expression level in DRG.
Recently, serine phosphorylation of HMGB1 has been
demonstrated to be essential for this translocation event,
although the kinase responsible for this mechanism has
yet to be identified [22]. Zhang et al. demonstrated
CaMKIV-mediated LPS-induced HMGB1 production by
translocating the HMGB1 to the nucleus in macrophages
[11]. These results indicate different mechanisms under-
lying the regulation of HMGB1 by CaMKIV. Overall, the
data display a mechanism involving the relationship
between HMGB1 and CaMKIV in neurons.
Conclusion
Intrathecal administration of KN93, a CaMKIV inhibitor,
can reverse thermal hyperalgesia and mechanical allodynia
in STZ rats. These effects may be partially attributed to
the decreased expression of HMGB1 in DRG.
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